Quote of the Day
The most constructive lesson now lies in prevention by design. Adenoviral vectors still have scientific value in vaccines and gene delivery research. The goal is therefore sharper than simple abandonment. Researchers now have a defined protein target to modify or remove. If pVII or its critical epitope starts the harmful immune sequence, future developers can test safer vectors that preserve immunogenicity while avoiding this trigger. That possibility changes the tone of the discussion around COVID vaccine side effects. Scientists no longer need to speak only in broad associations or unresolved suspicion. They can work from a mapped antigen, a defined mutation, and a clearer susceptibility model. WHO said in 2021 that open, transparent, and evidence-based communication is essential to maintain trust. That principle still applies.
Surveillance systems detected rare blood clots from COVID vaccine campaigns. The scientific response then kept going until the biology became clearer. The new NEJM study does not answer every remaining question. It does, however, give medicine a credible molecular explanation and a practical route toward safer adenoviral vaccine design. That is the most useful takeaway from this long debate. The problem was rare, the mechanism was obscure, and the investigation kept moving until the evidence sharpened. For readers trying to understand blood clots from COVID vaccine programs without falling into panic or denial, that is the central point. Medicine now has a much better explanation for what happened, why it happened rarely, and how future vaccine engineering may reduce the risk even further. That progress also gave researchers a clearer path toward safer vectors, better screening, and more confident public communication about risk.
Bruce Abrahamse
March 25, 2026
This is why some people had blood clots from the COVID-19 vaccine and others didn’t
Please note that this is not one of the COVID-19 mRNA vaccines that so many people had concerns about.
Also note that the frequency of the blood clots was about 4 people per one million doses with the Johnson & Johnson vaccine. With the AstraZeneca vaccine it was about 2 cases per 100,000 in those aged 60 or older and 2 to 3 cases per 100,000 under 60.
These rates are so low that it is difficult to detect in testing. But when many hundreds of millions of people received the vaccine, the correlation became noticeable.
